Androgen-Driven Fusion Genes and Chimeric Transcripts in Prostate Cancer

Androgens are steroid hormones governing the male reproductive development and function. As such, androgens and the key mediator of their effects, androgen receptor (AR), have a leading role in many diseases. Prostate cancer is a major disease where AR and its transcription factor function affect a...

Full description

Bibliographic Details
Main Authors: Mauro Scaravilli, Sonja Koivukoski, Leena Latonen
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Cell and Developmental Biology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fcell.2021.623809/full
_version_ 1818353357073416192
author Mauro Scaravilli
Sonja Koivukoski
Leena Latonen
author_facet Mauro Scaravilli
Sonja Koivukoski
Leena Latonen
author_sort Mauro Scaravilli
collection DOAJ
description Androgens are steroid hormones governing the male reproductive development and function. As such, androgens and the key mediator of their effects, androgen receptor (AR), have a leading role in many diseases. Prostate cancer is a major disease where AR and its transcription factor function affect a significant number of patients worldwide. While disease-related AR-driven transcriptional programs are connected to the presence and activity of the receptor itself, also novel modes of transcriptional regulation by androgens are exploited by cancer cells. One of the most intriguing and ingenious mechanisms is to bring previously unconnected genes under the control of AR. Most often this occurs through genetic rearrangements resulting in fusion genes where an androgen-regulated promoter area is combined to a protein-coding area of a previously androgen-unaffected gene. These gene fusions are distinctly frequent in prostate cancer compared to other common solid tumors, a phenomenon still requiring an explanation. Interestingly, also another mode of connecting androgen regulation to a previously unaffected gene product exists via transcriptional read-through mechanisms. Furthermore, androgen regulation of fusion genes and transcripts is not linked to only protein-coding genes. Pseudogenes and non-coding RNAs (ncRNAs), including long non-coding RNAs (lncRNAs) can also be affected by androgens and de novo functions produced. In this review, we discuss the prevalence, molecular mechanisms, and functional evidence for androgen-regulated prostate cancer fusion genes and transcripts. We also discuss the clinical relevance of especially the most common prostate cancer fusion gene TMPRSS2-ERG, as well as present open questions of prostate cancer fusions requiring further investigation.
first_indexed 2024-12-13T19:08:14Z
format Article
id doaj.art-e69a2649073540a0b3e48d4ec3619c9a
institution Directory Open Access Journal
issn 2296-634X
language English
last_indexed 2024-12-13T19:08:14Z
publishDate 2021-02-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Cell and Developmental Biology
spelling doaj.art-e69a2649073540a0b3e48d4ec3619c9a2022-12-21T23:34:29ZengFrontiers Media S.A.Frontiers in Cell and Developmental Biology2296-634X2021-02-01910.3389/fcell.2021.623809623809Androgen-Driven Fusion Genes and Chimeric Transcripts in Prostate CancerMauro ScaravilliSonja KoivukoskiLeena LatonenAndrogens are steroid hormones governing the male reproductive development and function. As such, androgens and the key mediator of their effects, androgen receptor (AR), have a leading role in many diseases. Prostate cancer is a major disease where AR and its transcription factor function affect a significant number of patients worldwide. While disease-related AR-driven transcriptional programs are connected to the presence and activity of the receptor itself, also novel modes of transcriptional regulation by androgens are exploited by cancer cells. One of the most intriguing and ingenious mechanisms is to bring previously unconnected genes under the control of AR. Most often this occurs through genetic rearrangements resulting in fusion genes where an androgen-regulated promoter area is combined to a protein-coding area of a previously androgen-unaffected gene. These gene fusions are distinctly frequent in prostate cancer compared to other common solid tumors, a phenomenon still requiring an explanation. Interestingly, also another mode of connecting androgen regulation to a previously unaffected gene product exists via transcriptional read-through mechanisms. Furthermore, androgen regulation of fusion genes and transcripts is not linked to only protein-coding genes. Pseudogenes and non-coding RNAs (ncRNAs), including long non-coding RNAs (lncRNAs) can also be affected by androgens and de novo functions produced. In this review, we discuss the prevalence, molecular mechanisms, and functional evidence for androgen-regulated prostate cancer fusion genes and transcripts. We also discuss the clinical relevance of especially the most common prostate cancer fusion gene TMPRSS2-ERG, as well as present open questions of prostate cancer fusions requiring further investigation.https://www.frontiersin.org/articles/10.3389/fcell.2021.623809/fullandrogen receptorandrogensprostate cancerfusion genefusion transcriptcastration-resistant prostate cancer
spellingShingle Mauro Scaravilli
Sonja Koivukoski
Leena Latonen
Androgen-Driven Fusion Genes and Chimeric Transcripts in Prostate Cancer
Frontiers in Cell and Developmental Biology
androgen receptor
androgens
prostate cancer
fusion gene
fusion transcript
castration-resistant prostate cancer
title Androgen-Driven Fusion Genes and Chimeric Transcripts in Prostate Cancer
title_full Androgen-Driven Fusion Genes and Chimeric Transcripts in Prostate Cancer
title_fullStr Androgen-Driven Fusion Genes and Chimeric Transcripts in Prostate Cancer
title_full_unstemmed Androgen-Driven Fusion Genes and Chimeric Transcripts in Prostate Cancer
title_short Androgen-Driven Fusion Genes and Chimeric Transcripts in Prostate Cancer
title_sort androgen driven fusion genes and chimeric transcripts in prostate cancer
topic androgen receptor
androgens
prostate cancer
fusion gene
fusion transcript
castration-resistant prostate cancer
url https://www.frontiersin.org/articles/10.3389/fcell.2021.623809/full
work_keys_str_mv AT mauroscaravilli androgendrivenfusiongenesandchimerictranscriptsinprostatecancer
AT sonjakoivukoski androgendrivenfusiongenesandchimerictranscriptsinprostatecancer
AT leenalatonen androgendrivenfusiongenesandchimerictranscriptsinprostatecancer